



Dr Shaun McNulty

PHD
CHIEF SCIENTIFIC OFFICER –
AWAKN LIFE SCIENCES

Dr Shaun McNulty is Chief Scientific Officer at Awakn Life Sciences, a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction.

Dr McNulty is an experienced CNS drug discovery expert and biotechnology executive. He has over 25 years of industry experience in the neuroscience drug discovery units of major pharmaceutical company, including Parke-Davis, Pfizer and GSK, in contract research for Charles River, and as CSO for several biotechnology companies.

Dr McNulty has worked to develop a range of CNS targeted drugs including Neurontin and Lyrica, specialising now in drug development strategy and the successful transfer of drug candidates into clinical trials.

Dr McNulty holds a D.Phil in CNS cell signalling from the University of York and researched neurotransmitter-regulated pathways controlling circadian function and behaviour at the University of Cambridge, UK.